Picture loading failed.

Anti-NOTCH2&3 therapeutic antibody (Pre-made Tarextumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-551-1mg 1mg 3090
GMP-Bios-ab-551-10mg 10mg 21890
GMP-Bios-ab-551-100mg 100mg 148000
GMP-Bios-ab-551-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-NOTCH2&3 therapeutic antibody (Pre-made Tarextumab biosimilar,Whole mAb)
INN Name Tarextumab
TargetNOTCH2&3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesOncoMed Pharmaceuticals
Conditions Approvedna
Conditions ActivePancreatic cancer;Small cell lung cancer
Conditions DiscontinuedSolid tumours
Development TechMorphoSys HuCAL Phage Display;XmAb Engineering Technology